Guangzhou Virotech Pharmaceutical Co., Ltd. was founded in January 2015 in Guangzhou, PR China as a biotechnology company to develop the Alphavirus M1 platform for oncolytic virus therapy.
Our current scientific focus is on the anti-tumour mechanisms of oncolytic virus M1 and its synergists, as well as related in vitro diagnostics.
Recombinant Oncolytic Virus
M1 for Infusion: M1-c6v1
As a modified Alphavirus M1 that enhances tumor lysis, M1-c6v1 is designed to be efficient and safe, administered by intravenous or arterial infusion. Lyophilised for convenient transport and storage, the product has broad efficacy against solid tumours
Pre-clinical studies performed under GLP in certified laboratories found no relevant toxicity in multiple species
M1-c6v1 1st Generation of M1 Virus
M1-aPD1/aPDL1/aCTLA42nd Generation of M1 Virus
M1 4.7Aparticle structure
Virotech is located in Guangzhou high-tech industrial development zone science city